GlassScriptPhysician profile
Peter J Kiefer
NPI 1386688158
$4,983.28
in general payments reported to CMS, 2019-2025
25 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $102 · 2021: $484 · 2022: $923 · 2023: $1,521 · 2024: $437 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,092.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,559.68 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $818.05 | 2019-2022 | |
| Novo Nordisk INC | $582.84 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Glaxosmithkline, LLC. | $329.19 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $329.07 | 2022-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $273.43 | 2020-2023 | Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $170.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $165.92 | 2022 | |
| Pfizer INC. | $146.01 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.76 | 2023 | |
| Idorsia Pharmaceuticals US INC | $91.45 | 2022 | |
| Lilly USA, LLC | $67.51 | 2022-2024 | Mounjaro |
| Exact Sciences Corporation | $43.45 | 2023-2024 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $39.11 | 2023 | Balcoltra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.46 | 2025 | Caplyta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $28.65 | 2023-2025 | Freestyle Libre 3 |
| Allergan, INC. | $23.24 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.75 | 2023 | Rexulti |
| Qol Medical, LLC | $21.19 | 2021 | |
| Smith+Nephew, INC. | $20.50 | 2023 | Grafix Pl |
| Biohaven Pharmaceuticals, INC. | $17.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.44 | 2023 | Eliquis |
| Amneal Pharmaceuticals LLC | $14.79 | 2023 | Unithroid |
| Lucid Diagnostics INC. | $14.39 | 2022 | |
| Edwards Lifesciences Corporation | $13.01 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kiefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.